PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

The 22q11 deletion syndromes are a group of conditions in which a characteristic spectrum of congenital cardiac defects may be associated with a wide range of noncardiological congenital anomalies.

A content creator who suffers from a genetic disorder known as 22q syndrome has been flooded with well-wishes after being hospitalized. Justin Gigliotti from Boston—who goes by the name "Justin G" on ...

Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to ...

PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients ...

Rebecca Osberg works to raise awareness of 22q Deletion Syndrome and create community. Born with congenital heart disease and many other problems, Rebecca Osberg struggled to succeed in school and ...

DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals (ZYNE), Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...

STATEN ISLAND, N.Y. -- When Ava Desiderato was born, she didn't cry. Moments later, she was airlifted to Philadelphia for emergency heart surgery. Nearly a decade later, she is a singer, dancer, ...

If you could ask for one thing this Christmas, what would it be? Would you ask to trend on Twitter? That is what Justin Gigliotti has asked; for everyone in the world to wish him Merry Christmas. The ...

A Naperville Central High School graduate is raising awareness for a common genetic condition as part of a worldwide initiative. Kapil Kumar, who graduated from Naperville Central in 2001, is ...

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ...